2019
p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas
Hsieh MH, Choe JH, Gadhvi J, Kim YJ, Arguez MA, Palmer M, Gerold H, Nowak C, Do H, Mazambani S, Knighton JK, Cha M, Goodwin J, Kang MK, Jeong JY, Lee SY, Faubert B, Xuan Z, Abel ED, Scafoglio C, Shackelford DB, Minna JD, Singh PK, Shulaev V, Bleris L, Hoyt K, Kim J, Inoue M, DeBerardinis RJ, Kim TH, Kim JW. p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. Cell Reports 2019, 28: 1860-1878.e9. PMID: 31412252, PMCID: PMC7048935, DOI: 10.1016/j.celrep.2019.07.027.Peer-Reviewed Original ResearchMeSH KeywordsAMP-Activated Protein KinasesAnimalsApoptosisCarcinoma, Squamous CellCell ProliferationFemaleGene Expression Regulation, NeoplasticGlucoseGlucose Transporter Type 1HumansMaleMembrane ProteinsMiceMice, Inbred NODMice, KnockoutMice, SCIDPhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesSignal TransductionSOXB1 Transcription FactorsTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsSquamous cell carcinomaCell carcinomaInsufficient therapeutic optionsBlood insulin levelsRenal glucose reabsorptionBlood glucose concentrationTumor growth inhibitionAnti-oxidative capacityMultiple anatomical sitesPI3K/AktGlucose restrictionSCC patientsWorse survivalKetogenic dietInsulin levelsTherapeutic optionsCancer mortalityGlucose reabsorptionSCC tumorsBlood glucoseSCC cellsAnatomical sitesCancer typesMetabolic vulnerabilitiesOxidative stress
2018
Glucose Transporter 1 Gene Variants Predict the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer
Do SK, Jeong JY, Lee SY, Choi JE, Hong MJ, Kang HG, Lee WK, Seok Y, Lee EB, Shin KM, Yoo SS, Lee J, Cha SI, Kim CH, Neugent ML, Goodwin J, Kim JW, Park JY. Glucose Transporter 1 Gene Variants Predict the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer. Annals Of Surgical Oncology 2018, 25: 3396-3403. PMID: 30062472, DOI: 10.1245/s10434-018-6677-1.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEarly-stage non-small cell lung cancerPrognosis of patientsCell lung cancerSingle nucleotide polymorphismsLung cancerStage non-small cell lung cancerSurvival of patientsSquamous cell carcinomaGlucose transporter 1 (GLUT1) geneBetter OSCurative surgerySurgical resectionWorse OSTumor histologyCell carcinomaStratified analysisBackgroundThis studyPatientsMultivariate analysisTransporter 1 geneConclusionsThis studyGene variantsPrognosisBad genotypes
2017
The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition
Goodwin J, Neugent ML, Lee SY, Choe JH, Choi H, Jenkins DMR, Ruthenborg RJ, Robinson MW, Jeong JY, Wake M, Abe H, Takeda N, Endo H, Inoue M, Xuan Z, Yoo H, Chen M, Ahn JM, Minna JD, Helke KL, Singh PK, Shackelford DB, Kim JW. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nature Communications 2017, 8: 15503. PMID: 28548087, PMCID: PMC5458561, DOI: 10.1038/ncomms15503.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overAnimalsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell Line, TumorCohort StudiesDeoxyglucoseFemaleFluorodeoxyglucose F18Gene Expression ProfilingGene Expression Regulation, NeoplasticGlucoseGlucose Transporter Type 1GlycolysisHumansHydroxybenzoatesLungLung NeoplasmsMaleMiceMice, NudeMiddle AgedPhenotypePositron-Emission TomographyPrognosisSurvival AnalysisUp-RegulationXenograft Model Antitumor AssaysConceptsNon-small cell lung cancerSquamous cell carcinomaLung SqCCCell carcinomaNSCLC subtypesGlycolytic inhibitionLung squamous cell carcinomaCell lung cancerPatient-derived xenograftsNSCLC tumor samplesNSCLC cell linesCancer Genome AtlasClinical presentationPoor prognosisTherapeutic optionsLung cancerPredominant subtypeDistinct metabolic phenotypesSelective vulnerabilityLung adenocarcinomaMurine modelTherapeutic strategiesSqCCTumor samplesMetabolic signatures